MARKET INTELLIGENCE·CDMO Deal
Merck's Alimatravir Licensing Reshapes HIV PrEP Market Access Ahead of Regulatory Approval
Merck's voluntary licensing of alimatravir for HIV PrEP, preceding regulatory submissions, signals a proactive market access strategy mirroring Gilead. This move impacts global supply chains by diversifying manufacturing potential and accelerates patient access. Procurement directors must prepare for multi-source API strategies, while regulatory affairs heads should anticipate complex, staggered approvals and market entry. Business development executives should evaluate this model for pipeline assets.
90-Day Activity